Company news

Endonovo Therapeutics, Inc. news in 2022

Endonovo Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Endonovo Announces Advancement of International “Go to Market” Initiative

December 19, 2022

Endonovo Announces Plans for Spin-off of Medical IP and Assets

December 15, 2022

Endonovo Launches Telehealth Initiative

December 13, 2022

Endonovo Names Ira Weisberg President to Guide Global Medical Expansion

November 30, 2022

Endonovo announces plan to explore strategic alternatives for its SofPulse® medical device assets

November 17, 2022

Endonovo Therapeutics Issues Corporate Update

November 7, 2022

Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company

September 27, 2022

Endonovo Therapeutics Releases Comparative Analysis Demonstrating

July 28, 2022

Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management

July 21, 2022

Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company

June 9, 2022

Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products

April 25, 2022

$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement

April 11, 2022

Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo

March 1, 2022

Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance

February 16, 2022